ScripKymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa
ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
ScripData presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate
ScripSanofi’s immunology pipeline has suffered a couple of high-profile setbacks recently so the proposed acquisition of Blueprint Medicines Corp and Ayvakit, its already-approved therapy for advanced sy